Mirror Biologics, Inc. Closes a $14 Million Financing Round

Mirror Biologics, Inc., a clinical-stage immunotherapy company specializing in the development, manufacturing, commercialization, and clinical translation of next-generation therapeutic in-situ vaccines for cancer and infectious diseases, closed a $14 million…

Continue Reading Mirror Biologics, Inc. Closes a $14 Million Financing Round